down arrow

Laurus Labs

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE947Q01028
  • NSEID: LAURUSLABS
  • BSEID: 540222
INR
604.35
40.95 (7.27%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 21.01 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Laurus Labs
Divi's Lab.
Suven Pharma
Cipla
Sun Pharma.Inds.
Torrent Pharma
Ajanta Pharma
Piramal Pharma
Syngene Intl.
J B Chemicals &
Mankind Pharma
Why is Laurus Labs Ltd ?
1
High Management Efficiency with a high ROCE of 18.89%
2
Poor long term growth as Operating profit has grown by an annual rate 8.90% of over the last 5 years
3
The company has declared positive results in Dec'2024 after 7 consecutive negative quarters
  • PAT(Q) At Rs 92.30 cr has Grown at 298.9 %
  • OPERATING PROFIT TO INTEREST(Q) Highest at 4.93 times
  • PBDIT(Q) Highest at Rs 285.15 cr.
4
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like MACD, KST and OBV
5
With ROCE of 5.2, it has a Expensive valuation with a 4.8 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 30.73%, its profits have risen by 6.6% ; the PEG ratio of the company is 23.5
6
High Institutional Holdings at 38.3%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
7
Market Beating Performance
  • Even though the market (BSE 500) has generated negative returns of -1.04% in the last 1 year, the stock has been able to generate 30.73% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Laurus Labs should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Laurus Labs for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Laurus Labs
31.7%
0.84
36.66%
SENSEX
0.45%
0.02
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
14.95%
EBIT Growth (5y)
8.90%
EBIT to Interest (avg)
8.78
Debt to EBITDA (avg)
1.75
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.97
Tax Ratio
29.85%
Dividend Payout Ratio
26.86%
Pledged Shares
2.69%
Institutional Holding
38.30%
ROCE (avg)
19.17%
ROE (avg)
19.29%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
152
Industry P/E
33
Price to Book Value
7.35
EV to EBIT
72.92
EV to EBITDA
37.81
EV to Capital Employed
4.82
EV to Sales
6.28
PEG Ratio
23.53
Dividend Yield
0.14%
ROCE (Latest)
5.21%
ROE (Latest)
3.17%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company
PAT(Q)

At Rs 92.30 cr has Grown at 298.9 %

OPERATING PROFIT TO INTEREST(Q)

Highest at 4.93 times

PBDIT(Q)

Highest at Rs 285.15 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 20.15%

PBT LESS OI(Q)

Highest at Rs 121.26 cr.

EPS(Q)

Highest at Rs 1.71

-6What is not working for the Company
ROCE(HY)

Lowest at 5.58 %

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 44.92 cr

DEBT-EQUITY RATIO(HY)

Highest at 0.68 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.89 times

Loading Valuation Snapshot...
Here's what is working for Laurus Labs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 121.26 cr has Grown at 276.70 %
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 92.30 cr has Grown at 298.9 %
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 4.93 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit (PBDIT) - Quarterly
Highest at Rs 285.15 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 20.15%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 121.26 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 92.30 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 1.71
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Laurus Labs
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 44.92 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio - Half Yearly
Highest at 0.68 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio- Half Yearly
Lowest at 2.89 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio